Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138236 | 0.71 | ASGR1 (0.32) | — | |
| SCHEMBL25349590 | 0.70 | LMNA (0.51) | LMNAUSP2OPRM1KMT2A | |
| SCHEMBL12861373 | 0.69 | KMT2A (0.35) | LMNAALDH1A1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL6138032 | 0.69 | OPRM1 (0.34) | LMNAOPRM1OPRL1KMT2A | |
| SCHEMBL16095601 | 0.68 | NPC1 (0.44) | LMNAALDH1A1HSD11B1KMT2A | |
| SCHEMBL12861376 | 0.67 | LMNA (0.31) | LMNA | |
| SCHEMBL12861258 | 0.67 | LMNA (0.34) | LMNATSHRUSP2OPRM1OPRL1 | |
| SCHEMBL12861215 | 0.67 | LMNA (0.31) | LMNA | |
| SCHEMBL12861276 | 0.67 | BDKRB2 (0.40) | CYP1A2OPRM1OPRL1OPRK1 | |
| SCHEMBL6138301 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | disclosed |
| CN-1176066-C | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ɪά��ʵ���� | 2004-11-17 | — | — | CN | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| CN-1330067-A | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ADIR (FR) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | CHRNA1, CHRNA4, CHRNB1 | CYP2C19 637/4885CYP1A2 238/4885LMNA 3499/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | CYP2C19 745/4885CYP1A2 216/4885LMNA 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.